Atlas Trials

Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Clinical trial NCT04682210 · UNKNOWN

Trial details

NCT number
NCT04682210
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
HCCAdjuvant TherapyImmunotherapy
Start date
2020-12-01
Primary completion
2023-12-01
Enrollment
246

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.